ECE2015 Guided Posters Endocrine tumours and neoplasia – NETS (9 abstracts)
Association of angiopoietin/TIE2 plasma level and VEGF system with progression in gastroenteropancreatic neuroendocrine tumors
Miguel Sampedro-Nuñez 1, , Ana Ramos-Leví 1, , Alicia Vicuña 1 , Sandra Campos 1 , Ana Serrano 1, , Ana Rodríguez-Muñoz 1, , Rebeca Martínez-Hernández 1, , Elena Martín-Pérez 2, , Magdalena Adrados 3, & Mónica Marazuela 1,
1Department of Endocrinology and Nutrition, Hospital Universitario de la Princesa, Madrid, Spain; 2Department of General and Gastrointestinal Surgery, Hospital Universitario de la Princesa, Madrid, Spain; 3Department of Pathology, Hospital Universitario de la Princesa, Madrid, Spain; 4Universidad Autónoma de Madrid, Instituto de Investigación Sanitaria Princesa, Madrid, Spain.
Introduction: Angiopoietins (ANG) -1 and 2, their receptor TIE2, and the vascular endothelial growth factor (VEGF) are involved in the process of angiogenesis. However, their role in the pathogenesis and development of gastroenteropancreatic neuroendocrine tumours (GEP-NETs) is not completely understood. In a previous study of 42 patients with GEP-NET, we observed an elevation of these serum markers, especially in those with metastatic disease. The objective of this study was to analyse the relationship between plasma levels of the ANG/TIE2-VEGF system in patients with GEP NETs who exhibited progression after 3 years of follow-up.
Methods and materials: 26 Patients with GEP-NETs were studied. Primary location of tumours was pancreas (n=13) and intestine (n=13). Plasma levels of ANG-1, ANG-2, TIE2 and VEGF were determined by ELISA. We evaluated response to medical and/or surgical treatment using clinical and radiological criteria and patients were assigned to three categories (complete remission, stable disease or progressive response), accordingly. Statistical nonparametric analysis tests was performed.
Results: At diagnosis, 13 patients had positive regional lymph nodes and 13 distant metastases. Thirteen patients achieved complete response, six had stabilization and seven were classified as disease progression. Plasma TIE-2 levels at initial evaluation were higher in patients who had progressive disease (31 803.17±5495.55 pg/ml) vs those who had complete response (18 930.00±3914.20 pg/ml) or remained stable (25 236.67±1072.40 pg/ml) (P=0.012). No differences were found in these angiogenic markers when comparing primary tumour location (pancreas or intestine), the presence or absence of metastases, or response to somatostatin analogue therapy.
Conclusion: TIE2 plasma values are higher in patients with GEP-NETs with progressive disease. This suggests a possible involvement of ANG/TIE2 system in the pathogenesis of GEP-NETs and a possible relevance as diagnostic and/or therapeutic target.
Volume 37
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more